QQ客服 官方微博 反馈留言

	VRK1 promotes cisplatin resistance by up-regulating c-MYC via c-Jun activation and serves as a therapeutic target in esophageal squamous cell carcinoma
	Liu, Zhen-Chuan; Cao, Kuo; Xiao, Zhao-Hua; Qiao, Liang; Wang, Xue-Qing; Shang, Bin; Jia, Yang; Wang, Zhou
刊名	ONCOTARGET
	2017
卷号	8期号:39页码:65642-65658
关键词	esophageal squamous cell carcinoma vaccinia-related kinase 1 cisplatin c-Jun c-MYC
DOI	10.18632/oncotarget.20020
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4590454
专题	山东大学
作者单位	Shandong Univ, Dept Thorac Surg, Shandong
推荐引用方式 GB/T 7714	Liu, Zhen-Chuan,Cao, Kuo,Xiao, Zhao-Hua,et al. VRK1 promotes cisplatin resistance by up-regulating c-MYC via c-Jun activation and serves as a therapeutic target in esophageal squamous cell carcinoma[J]. ONCOTARGET,2017,8(39):65642-65658.
APA	Liu, Zhen-Chuan.,Cao, Kuo.,Xiao, Zhao-Hua.,Qiao, Liang.,Wang, Xue-Qing.,...&Wang, Zhou.(2017).VRK1 promotes cisplatin resistance by up-regulating c-MYC via c-Jun activation and serves as a therapeutic target in esophageal squamous cell carcinoma.ONCOTARGET,8(39),65642-65658.
MLA	Liu, Zhen-Chuan,et al."VRK1 promotes cisplatin resistance by up-regulating c-MYC via c-Jun activation and serves as a therapeutic target in esophageal squamous cell carcinoma".ONCOTARGET 8.39(2017):65642-65658.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。